1. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate. 2006; 66:1285–1291.
2. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol. 1995; 18:51–64.
3. Long MA, Husband JE. Features of unusual metastases from prostate cancer. Br J Radiol. 1999; 72:933–941.
4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000; 31:578–583.
5. Moura FM, Garcia LT, Castro LP, Ferrari TC. Prostate adenocarcinoma manifesting as generalized lymphadenopathy. Urol Oncol. 2006; 24:216–219.
6. McGarry RC. Superior vena cava obstruction due to prostate carcinoma. Urology. 2000; 55:436.
7. Kosugi S, Mizumachi S, Kitajima A, Igarashi T, Hamada T, Kaya H, et al. Prostate cancer with supraclavicular lymphadenopathy and bulky abdominal tumor. Intern Med. 2007; 46:1135–1138.
8. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ. Immunohistochemical labelling for prostate specific antigen in non-prostatic tissues. Pathol Res Pract. 1996; 192:233–237.
9. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J Urol. 1996; 155:994–998.